Association between serum level soluble programmed cell death ligand 1 and prognosis in patients with non‐small cell lung cancer treated with anti‐PD ‐1 antibody-Reference-Cited by-同舟云学术

Association between serum level soluble programmed cell death ligand 1 and prognosis in patients with non‐small cell lung cancer treated with anti‐PD ‐1 antibody

Published:2020-10-27 Issue:12 Volume:11 Page:3585-3595
ISSN:1759-7706
Container-title:Thoracic Cancer
language:en
Short-container-title:Thorac Cancer

Author:

Murakami Shuji¹^ORCID,Shibaki Ryota¹,Matsumoto Yuji¹,Yoshida Tatsuya¹^ORCID,Goto Yasushi¹,Kanda Shintaro¹,Horinouchi Hidehito¹^ORCID,Fujiwara Yutaka¹,Yamamoto Noboru¹,Ohe Yuichiro¹

Affiliation:

1. Department of Thoracic Oncology National Cancer Center Hospital Tokyo Japan

Publisher

Wiley

Subject

Pulmonary and Respiratory Medicine,Oncology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/1759-7714.13721

Reference39 articles.

1. Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: Four-Arm Cooperative Study in Japan

2. Comparison of Four Chemotherapy Regimens for Advanced Non–Small-Cell Lung Cancer

3. Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs